Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT01289132 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.

NCT ID: NCT01264692 Completed - Clinical trials for Essential Hypertension

Essential Hypertension

REDUCE-1
Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

NCT ID: NCT01258673 Completed - Clinical trials for Essential Hypertension

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.

NCT ID: NCT01256411 Completed - Clinical trials for Essential Hypertension

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.

NCT ID: NCT01237873 Completed - Clinical trials for Essential Hypertension

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension. This study is being conducted to support registration of the fixed combination of aliskiren/amlodipine in the treatment for hypertension in Japan.

NCT ID: NCT01237223 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and < 110 mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.

NCT ID: NCT01198249 Completed - Clinical trials for Essential Hypertension

Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This study is aimed to evaluate the pharmacokinetics and the drug-drug interaction among anti-hypertension drugs-amlodipine, losartan, and hydrochlorothiazide. This pilot study provides useful information to develop a new fixed dose combination drug.

NCT ID: NCT01195805 Completed - Clinical trials for Essential Hypertension

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

hass
Start date: August 2010
Phase: N/A
Study type: Interventional

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

NCT ID: NCT01180413 Completed - Clinical trials for Essential Hypertension

Intensive Vasodilator Therapy in Patients With Essential Hypertension

Vasomore
Start date: December 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether add-on of intensive vasodilator therapy can improve the coronary perfusion and reduce the total peripheral resistance in patients with ongoing treatment for essential hypertension.

NCT ID: NCT01146938 Completed - Clinical trials for Essential Hypertension

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

Start date: May 2010
Phase: Phase 1
Study type: Interventional

To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers